Get the Stockscreener App
12.00
3.36%
0.39
After Hours:
12.00
Xencor Inc stock is traded at $12.00, with a volume of 646.48K.
It is up +3.36% in the last 24 hours and up +3.54% over the past month.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
See More
Previous Close:
$11.61
Open:
$11.72
24h Volume:
646.48K
Relative Volume:
0.88
Market Cap:
$880.06M
Revenue:
$125.58M
Net Income/Loss:
$-92.14M
P/E Ratio:
-9.6587
EPS:
-1.2424
Net Cash Flow:
$-138.27M
1W Performance:
+6.01%
1M Performance:
+3.54%
6M Performance:
+39.53%
1Y Performance:
-6.76%
1-Day Range:
$11.45
$12.08
1-Week Range:
$11.22
$12.36
52-Week Range:
$6.92
$18.69
Xencor Inc Stock (XNCR) Company Profile
Name
Xencor Inc
Sector
Industry
Phone
626-305-5900
Address
465 N. HALSTEAD ST., PASADENA, CA
Compare XNCR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
12.00 | 851.46M | 125.58M | -92.14M | -138.27M | -1.2424 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Initiated | Truist | Buy |
| Oct-29-25 | Upgrade | Barclays | Underweight → Overweight |
| Sep-17-25 | Resumed | Barclays | Underweight |
| Sep-03-25 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-21-25 | Initiated | William Blair | Outperform |
| Dec-12-24 | Initiated | Wells Fargo | Overweight |
| Dec-02-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-16-24 | Reiterated | BTIG Research | Buy |
| Feb-28-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-19-23 | Initiated | BofA Securities | Buy |
| Dec-06-22 | Initiated | Cowen | Outperform |
| Oct-13-22 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Jan-21-22 | Initiated | SMBC Nikko | Outperform |
| Dec-15-21 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Feb-24-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-04-20 | Initiated | Barclays | Underweight |
| Feb-25-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-30-20 | Initiated | RBC Capital Mkts | Outperform |
| Nov-20-19 | Resumed | Guggenheim | Neutral |
| Aug-07-19 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-07-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-13-19 | Initiated | Mizuho | Buy |
| Apr-12-19 | Initiated | Guggenheim | Buy |
| Mar-27-19 | Initiated | Berenberg | Buy |
| Mar-15-19 | Initiated | Raymond James | Outperform |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| Mar-28-18 | Resumed | Leerink Partners | Outperform |
| Mar-02-17 | Initiated | Instinet | Neutral |
| Mar-02-17 | Reiterated | Wedbush | Outperform |
| Oct-04-16 | Initiated | Piper Jaffray | Overweight |
| Dec-22-15 | Initiated | Canaccord Genuity | Buy |
| Aug-05-15 | Reiterated | MLV & Co | Buy |
| Feb-12-15 | Reiterated | Oppenheimer | Outperform |
| Jan-28-15 | Reiterated | MLV & Co | Buy |
| Jul-11-14 | Initiated | Oppenheimer | Outperform |
View All
Xencor Inc Stock (XNCR) Latest News
Xencor’s Lung Cancer Trial Halted: What the Vudalimab Update Means for XNCR Investors - TipRanks
Jefferies Financial Group Inc. Takes Position in Xencor, Inc. $XNCR - MarketBeat
Xencor at Barclays Healthcare Conference: Pipeline Progress and Strategic Plans - Investing.com India
(XNCR) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Xencor at Leerink Global Healthcare: Strategic Development Insights - Investing.com Nigeria
Xencor, Inc. (NASDAQ:XNCR) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Xencor SVP Eckert sells $17,747 in shares - Investing.com Nigeria
Xencor faces royalty dispute with Alexion over Ultomiris sales - Investing.com Nigeria
Xencor (NASDAQ:XNCR) CEO Sells $72,798.12 in Stock - MarketBeat
John Desjarlais Sells 4,118 Shares of Xencor (NASDAQ:XNCR) Stock - MarketBeat
Xencor (NASDAQ:XNCR) SVP Sells $19,472.34 in Stock - MarketBeat
Xencor (NASDAQ:XNCR) SVP Celia Eckert Sells 3,244 Shares - MarketBeat
Xencor (NASDAQ:XNCR) VP Sells $27,572.04 in Stock - MarketBeat
Xencor (NASDAQ:XNCR) CEO Bassil Dahiyat Sells 14,870 Shares - MarketBeat
Xencor, Genentech to End Protein Therapeutics Collaboration - TipRanks
Royalty rift: Alexion cuts off US royalty payments to Xencor - MSN
Market Moves: What is the Moat Score of Xencor IncMarket Volume Summary & Weekly Watchlist of Top Performers - baoquankhu1.vn
Is Xencor Inc a strong candidate for buy and hold2025 Top Decliners & AI Driven Stock Movement Reports - baoquankhu1.vn
Aug Breakouts: Can Xencor Inc disrupt its industry2025 Technical Patterns & Low Risk High Reward Ideas - baoquankhu1.vn
Insider Buy: Can Xencor Inc sustain its profitabilityJuly 2025 Summary & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Retail Trends: Is Xencor Inc impacted by rising rates2025 Historical Comparison & Consistent Profit Trading Strategies - baoquankhu1.vn
Resistance Check: What is the long term forecast for Xencor Inc stock2025 Key Highlights & Community Consensus Picks - baoquankhu1.vn
Xencor, Inc. $XNCR Shares Sold by Vanguard Group Inc. - MarketBeat
Dahiyat, Xencor CEO, sells $80k in XNCR stock By Investing.com - Investing.com Australia
3,244-share sale planned by XNCR (NASDAQ: XNCR) — insider notice - Stock Titan
Insider sale and restricted vesting reported by Company (NASDAQ: XNCR) - Stock Titan
Xencor SVP Eckert sells $17,747 in shares By Investing.com - Investing.com Australia
Xencor faces royalty dispute with Alexion over Ultomiris sales By Investing.com - Investing.com Australia
Xencor (NASDAQ:XNCR) Shares Gap Down Following Insider Selling - MarketBeat
Xencor falls on royalty row with AstraZeneca (XNCR:NASDAQ) - Seeking Alpha
Royalty Rift: Alexion Cuts Off US Royalty Payments To Xencor - Bitget
Xencor (NASDAQ:XNCR) VP Sells $31,689.70 in Stock - MarketBeat
Insider Selling: Xencor (NASDAQ:XNCR) SVP Sells 1,492 Shares of Stock - MarketBeat
Xencor sr. VP Desjarlais sells $31,676 in stock - Investing.com South Africa
Xencor sr. VP Desjarlais sells $31,676 in stock By Investing.com - Investing.com Canada
Dahiyat, Xencor CEO, sells $80k in XNCR stock - Investing.com
Xencor: Buy Rating Reaffirmed on Pipeline Momentum Despite Ultomiris Royalty Headwind - TipRanks
Xencor Updates Outlook Amid Ultomiris Royalty Dispute - TipRanks
Xencor says Alexion disputes U.S. Ultomiris royalties; updates cash guidance to $380–400M - TradingView
Xencor Announces Change to Ultomiris® Royalty Revenue Forecast - Business Wire
XNCR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
(XNCR.O) | Stock Price & Latest News - Reuters
[144] Xencor Inc SEC Filing - Stock Titan
John Desjarlais plans to sell 2,663 XNCR shares (XNCR) — Form 144 notice - Stock Titan
Xencor at TD Cowen Conference: Strategic Focus on Oncology and Autoimmune - Investing.com Nigeria
Update Recap: Should value investors consider Xencor IncEarnings Recap Report & High Yield Equity Trading Tips - baoquankhu1.vn
Xencor, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Responsive Playbooks and the XNCR Inflection - Stock Traders Daily
XNCR PE Ratio & Valuation, Is XNCR Overvalued - Intellectia AI
Xencor (NASDAQ:XNCR) Stock Rating Lowered by Wall Street Zen - MarketBeat
Xencor, Inc. (XNCR) Investor Outlook: Unpacking the 113% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Xencor Inc Stock (XNCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.48%
1.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):